Xtl Biopharmaceuticals Ltd (XTLB) — 6-K Filings

6-K Filings (24)

• XTL Biopharma Files 6-K Announcing Share Purchase Agreement — Apr 29, 2026 Risk: medium
  XTL Biopharmaceuticals Ltd. filed a Form 6-K on April 29, 2026, reporting a Share Purchase Agreement. The filing includes a press release detailing this agreeme
• XTL Biopharma Reports H1 2025 Results Amid Shareholder Dispute — Dec 30, 2025 Risk: medium
  XTL Biopharmaceuticals Ltd. announced its financial results for the six months ended June 30, 2025, on December 30, 2025. The company is currently involved in a
• XTL Biopharma Faces Nasdaq Minimum Bid Price Deficiency — Dec 29, 2025 Risk: medium
  On December 24, 2025, XTL Biopharmaceuticals Ltd. received a notification letter from Nasdaq Listing Qualifications concerning a minimum bid price deficiency. T
• XTL Biopharma Subsidiary Sees CEO & CTO Resign — Dec 12, 2025 Risk: medium
  On December 11, 2025, Tal Klinger, CEO of Social Proxy Ltd., and Roee Klinger, CTO of Social Proxy Ltd., both wholly owned subsidiaries of XTL Biopharmaceutical
• XTL Biopharma CFO Resigns, New CFO Appointed — Dec 5, 2025 Risk: medium
  XTL Biopharmaceuticals Ltd. announced on December 5, 2025, that its Chief Financial Officer, Itay Weinstein, will resign effective December 11, 2025. His resign
• XTL Biopharmaceuticals Board Changes — Oct 23, 2025 Risk: low
  Doron Turjeman resigned from the Board of Directors of XTL Biopharmaceuticals Ltd. on October 21, 2025, for personal reasons. Noam Band, the CEO, was appointed
• XTL Biopharma Holds Shareholder Meeting — Jul 28, 2025 Risk: low
  XTL Biopharmaceuticals Ltd. announced on June 13, 2025, that its Annual and Extraordinary General Meeting of Shareholders would be held on July 21, 2025, in Bne
• XTL Biopharm Postpones Shareholder Meeting Due to Lack of Quorum — Jul 21, 2025 Risk: medium
  XTL Biopharmaceuticals Ltd. announced on July 21, 2025, the postponement of its annual and extraordinary shareholders' meeting originally scheduled for the same
• XTL Biopharma Sets Shareholder Meeting for July 21 — Jun 13, 2025 Risk: low
  XTL Biopharmaceuticals Ltd. announced on June 13, 2025, that it will hold its Annual and Extraordinary General Meeting of Shareholders on July 21, 2025. The mee
• XTL Biopharmaceuticals Appoints New CEO, Noam Band — Apr 7, 2025 Risk: medium
  On April 7, 2025, XTL Biopharmaceuticals Ltd. appointed Noam Band as its new Chief Executive Officer, succeeding Shlomo Shalev, who will remain as Chairman of t
• XTL Biopharma Grants Exclusive Sublicense to Biossil Inc. — Mar 4, 2025 Risk: medium
  On March 4, 2025, XTL Biopharmaceuticals Ltd. entered into a definitive Exclusive Sublicense Agreement with Biossil Inc. Under this agreement, XTL will grant Bi
• XTL Biopharma Settles with Social Proxy CEO, Shareholder Director Rights — Feb 3, 2025 Risk: low
  On November 19, 2024, XTL Biopharmaceuticals Ltd. announced a settlement agreement with Tal Klinger, CEO of its subsidiary The Social Proxy Ltd., and the previo
• XTL Biopharma Reports H1 2024 Results, Solar Project Term Sheet — Dec 30, 2024 Risk: medium
  XTL Biopharmaceuticals Ltd. announced its financial results for the six months ended June 30, 2024. The company also noted a binding term sheet entered into on
• XTL Biopharma Settles with Social Proxy CEO & Shareholders — Nov 19, 2024 Risk: medium
  XTL Biopharmaceuticals Ltd. filed a Form 6-K on November 19, 2024, detailing a settlement agreement entered into on November 11, 2024. This agreement involves t
• XTL Biopharma Settles Social Proxy Acquisition Claims — Nov 12, 2024 Risk: low
  On November 11, 2024, XTL Biopharmaceuticals Ltd. entered into a settlement agreement with the CEO and previous shareholders of The Social Proxy Ltd., which XTL
• XTL Biopharma Faces Controversy with AI Subsidiary — Oct 15, 2024 Risk: medium
  XTL Biopharmaceuticals Ltd. announced on October 15, 2024, that a controversy has arisen concerning its wholly owned subsidiary, The Social Proxy Ltd., an AI we
• XTL Biopharmaceuticals Acquires AI Data Firm Social Proxy — Aug 14, 2024 Risk: medium
  On August 14, 2024, XTL Biopharmaceuticals Ltd. announced the completion of its acquisition of The Social Proxy Ltd., an AI web data company. The transaction in
• XTL Biopharma Announces Meeting Results — Jul 22, 2024 Risk: low
  XTL Biopharmaceuticals Ltd. announced the results of its Annual and Extraordinary General Meeting of Shareholders held on July 22, 2024. The meeting was origina
• XTL Biopharma Sets Shareholder Meeting for July 22 — Jun 12, 2024 Risk: low
  XTL Biopharmaceuticals Ltd. announced on June 12, 2024, that it will hold its Annual and Extraordinary General Meeting of Shareholders on July 22, 2024, in Bnei
• XTL Biopharmaceuticals to Acquire AI Data Company Social Proxy — Jun 5, 2024 Risk: medium
  On June 5, 2024, XTL Biopharmaceuticals Ltd. (XTL) announced it entered into a definitive share purchase agreement to acquire THE SOCIAL PROXY Ltd. (Social Prox
• XTL Biopharma Reports Q1 2024 Results, Seeks Strategic Partner — May 13, 2024 Risk: medium
  XTL Biopharmaceuticals Ltd. announced its financial results for the three months ended March 31, 2024. The company, which focuses on treatments for Lupus diseas
• XTL Biopharma Regains Nasdaq Minimum Bid Price Compliance — Apr 2, 2024 Risk: medium
  On April 2, 2024, XTL Biopharmaceuticals Ltd. received formal notification from the Nasdaq Stock Market that it has regained compliance with the minimum bid pri
• XTL Biopharma Schedules Shareholder Meeting for April 30 — Mar 21, 2024 Risk: low
  XTL Biopharmaceuticals Ltd. announced on March 20, 2024, that it will hold an Extraordinary General Meeting of Shareholders on April 30, 2024, at 4:00 p.m. Isra
• XTL Biopharma to Acquire AI Web Data Firm Social Proxy — Mar 20, 2024 Risk: medium
  On March 20, 2024, XTL Biopharmaceuticals Ltd. announced it has entered into a binding term sheet with THE SOCIAL PROXY Ltd., an AI web data company. This agree

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX